The effect of percutaneous balloon mitral valvuloplasty on N-terminal- pro B-type natriuretic peptide plasma levels in mitral stenosis

International Heart Journal

Volumn 48, Issue 5, 2007, Pages 579-590

  Selcuk, Mehmet Timur ^a   Selcuk, Hatice ^a   Maden, Orhan ^a   Erbay, Ali Riza ^a   Temizhan, Ahmet ^a   Aksu, Tolga ^a   Saydam, Gul Sevim ^a   Korkmaz, Sule ^a  

^a TURKIYE YUKSEK IHTISAS HOSPITAL   (Turkey)

Author keywords

Mitral balloon; NT proBNP; Pulmonary hypertension

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; BALLOON CATHETER; CARDIOPULMONARY HEMODYNAMICS; CONTROLLED STUDY; ECHOCARDIOGRAPHY; FEMALE; FUNCTIONAL STATUS; HEART LEFT ATRIUM PRESSURE; HUMAN; LINEAR REGRESSION ANALYSIS; LUNG ARTERY PRESSURE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE STENOSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; RHEUMATIC HEART DISEASE; TRANSLUMINAL VALVULOPLASTY;

ADOLESCENT; ADULT; AGED; BALLOON DILATATION; BLOOD PRESSURE; CARDIAC OUTPUT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MITRAL VALVE STENOSIS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PULMONARY ARTERY; TREATMENT OUTCOME;

EID: 36749059927     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.48.579     Document Type: Article

References (35)

1. Cheung BM, Kumana CR. Natriuretic peptides-relevance in cardiovascular disease. JAMA 1998; 280: 1983-4.
2. Yoshimura M, Yasue H, Morita E, et al. Hemodynanik, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure. Circulation 1991; 84:1581-8.
3. Talwar S, Siebenhofer A, Williams B, Ng L. Influence of hypertension, left ventricular hypertrophy, and left ventricular systolic dysfunction on plasma N terminal proBNP Heart 2000; 83: 278-82.
4. Hasegawa K, Fujiwara H, Doyama K, et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993; 88: 372-80.
5. Pfister R, Scholz M, Wielckens Y, Erdmann F, Schneider CA. Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail 2004; 6: 289-93.
6. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Eno J Med 1998; 339: 321-8. (Review)
7. Chen HH, Burnett JC. Natriuretic peptides in the pathophysiology of congestive heart failure. Curr Cardiol Rep 2000; 2: 198-205. (Review)
8. Yoshimura M, Yasue H, Okumura K, et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87: 464-9.
9. Nagaya N, Nishikimi T, Okano Y, et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31: 202-8.
10. Tulevski, II, Groenink M, van Der Wall EE, et al. Increased brain and atrial natriuretic peptides in patients with chronic right ventricular pressure overload. correlation between plasma neurohormones and right ventricular dysfunction. Heart 2001; 86: 27-30.
11. Bonow RO, Braunwald E. Valvular Heart Disease. In: Braunwald E, ed. Heart Disease. 7th ed. Philadelphia, Saunders Company; 2005: 1553-632.
12. Maoqin S, Guoxiang H, Zhiyuan S, et al. The clinical and hemodynamic results of mitral balloon va1vuloplasty for patients with mitral stenosis complicated by severe pulmonary hypertension. Eur J Intern Med 2005; 16: 413-8.
13. Sanchez PL, Rodriguez-Alemparte K Inglessis I, Palacios IF. The finpact of age in the immediate and longterm outcomes of percutaneous mitral balloon valvuloplasty. J Interv Cardiol 2005; 18: 217-25.
14. Reyes VP, Raju BS, Wyme J, et al. Percutaneous balloop valvuloplasty compared with open surgical commissurotomy for mitral stenosis. N Engl J Med 1994; 331: 961-7.
15. Dean LS, Mickel M, Bonan R, et al. Four-year follow-up of patients undergoing percutmeous balloon mitral commissurotomy. A report from the National Heart, Lung, and Blood Institute Balloon Valvdoplasty Registry. J Am Coll Cardiol 1996; 28: 1452-7.
16. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-67. (Review)
17. Wilkins GT, Weyman AE, Abascal VM, Block PC, Palacios IF. Percutanecus balloon dilatation of the mitral Valve: an analysis of echocardiographic variables related to outcome and the mechanism of dilatation. Br Heart J 1988; 60:299-308.
18. Inoue Y, Owaki T, Nakamura T, Kitamura F, Miyamoto N. Clinical application of transvenous mitral commissurotomy by a new balloon catheter. J Thorac Cardiovasc Surg 1984; 87: 394-402.
19. Sellers RD, Levy MJ, Amplatz K, Lillehei CW. Left retrograde cardioangiograhy in acquired cardiac disease: technic, indications and interpretations in 700 cases. Am J Cardiol 1964; 14: 437-47.
20. Iltumur K, Karabulut A, Yokus B, Yavuzkir M, Taskesen T, Toprak N. N-terminal proBNP plasma levels correlate with severity of mitral stenosis. J Heart Valve Dis 2005; 14: 735-41.
21. Golbasy Z, Ucar O, Yuksel AG, Gulel O, Aydogdu S, Ulusoy V. Plasma brain natriuretic peptide levels in patients with rheumatic heart disease. Eur J Heart Fail 2004; 6: 757-60.
22. Arat-Ozkan A, Kaya A, Yigit Z, et al. Serum N-terminal pro-BNP levels correlate with symptoms and echocardiographic findings in patients with initial stenosis. Echocardiography 2005; 22: 473-8.
23. Sudoh T, Kangawa K, Minamino N, Matsuo H. A new natriuretic peptide in porcine brain. Nature 1989; 332: 78-81.
24. Mukoyama M, Nakao K, Hosoda K, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87: 1402-12.
25. Inoue S, Murakami Y, Sano K, Katoh H, Shimada T. Atrium as a source of brain natriuretic polypeptide in patients with atrial fibrillation. J Card Fail 2000; 6: 92-6.
26. Ohta Y, Shimada T, Yoshitomi H, et al. Drop in plasma brain natriurefic peptide levels after successful direct current cardioversion in chronic atrial fibrillation. Can J Cardiol 2001; 17: 415-20.
27. Nakamura M, Kawata Y, Yoshida H, et al. Relationship between plasma atrial and brain natriuretic peptide concentration and hemodynamic parameters during percutaneous transvenous mitral valvulotomy in patients with mitral stenosis. Am Heart J 1992; 124: 1283-8.
28. Tsioufis C, Stougiannos P, Taxiarchou E, et al. The interplay between haemodynamic load, brain natriuretic peptide and left atial size in the early stages of essential hypertension. J Hypertens 2006; 24: 965-72.
29. Hill NS, Klinger JR, Warburton RR, Pietras L, Wrenn DS. Brain natriuretic peptide: possible role in the modulation of hypoxic pulmonary hypertension. Am J Physiol 1994; 266: L308-15.
30. Lang CC, Coutie WJ, Struthers AD, Dhillon DP, Winter JH, Lipworth BJ. Elevated levels of brain natriuretic peptide in acute hypoxaemic chronic obstructive pulmonary disease. Clin Sci (Lond) 1992; 83: 529-33.
31. Nagaya N, Nishikimi T, Uematsu M, et al. Secretion patterns of brain natriuretic peptide and atrial natriuretic peptide in patients with or without pulmonary hypertension complicating atrial septal defect. Am Heart J 1998; 136: 297-301.
32. Leuchte HH, Holzapfel M, Baumgartner RA, et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J Am Coll Cardiol 2004; 43: 764-70.
33. Pieralli F, Olivotto I, Vanni S, et al. Usefulness of bedside testing for brain natriuretic peptide to identify right ventricular dysfunction and outcome in normotensive patients with acute pulmonary embolism. Am J Cardiol 2006; 97:1386-90.
34. Kruger S, Graf J, Merx MW, et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J 2004; 147: 60-5.
35. Gobinet-Georges A, Valli N. Filliatre H, Dubernet WF, Dedeystere O. Bordenave L. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma. Clin Chem Lab Med 2000; 38: 519-23.